9 results
DEFM14A
SQZB
SQZ Biotechnologies Co
23 Jan 24
Proxy related to merger
4:31pm
and experimental (R&D) expenditures under section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company … during the year and resulted in the capitalization of R&D costs of $66.8 million. The Company is amortizing these costs for tax purposes over 5 years
PREM14A
SQZB
SQZ Biotechnologies Co
12 Jan 24
Preliminary proxy related to merger
8:57am
to capitalize and amortize research and experimental (R&D) expenditures under section 174 for tax years beginning after December 31, 2021. This rule became … effective for the Company during the year and resulted in the capitalization of R&D costs of $66.8 million. The Company is amortizing these costs for tax
PRE 14A
SQZB
SQZ Biotechnologies Co
10 Apr 23
Preliminary proxy
4:31pm
President R&D, Chief Medical Officer, and Chief Executive Officer, from September 2006 until February 2015, when it was acquired by Intrexon … and Chief Medical Officer and Senior Vice President of R&D at Viracta Therapeutics from January 2016 to January 2020. Her prior experience also
8-K
EX-99.1
07dva 20sr6
31 May 22
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease
4:52pm
8-K
lnfwkraheboo523u
19 May 22
Regulation FD Disclosure
4:05pm
- Prev
- 1
- Next